Skip to main content

Advertisement

SpringerLink
Log in

The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism

  • Research Article
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Recent studies hint that Ginsenoside is involved in cancer prevention and treatment. In this study, we investigated the effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma (CRC) cells and its mechanism. The resistance reversion effect of Ginsenoside Rh2 in CRC cells was analyzed using CCK-8 assay. After treating with Ginsenoside Rh2, the cell cycle distribution and cellular apoptosis were analyzed by flow cytometry, cell migration was determined by transwell migration assay, the expression of drug-resistance genes and proteins were evaluated using quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot, respectively. Ginsenoside Rh2 could enhance the cytotoxicity of 5-FU in drug-resistant CRC cells (LoVo/5-FU and HCT-8/5-FU). Treatment with Ginsenoside Rh2 could result in an increase of cell numbers in G0/G1 phase accompanied with a decrease in S-phase, and induced cellular apoptosis in drug-resistant CRC cells. In addition, the migration process and EMT process of drug-resistant CRC cells were suppressed by treatment of Ginsenoside Rh2. Compared to control group, expression of drug-resistance genes, such as MRP1, MDR1, LRP and GST, were negatively correlated to Ginsenoside Rh2. All these results indicated that Ginsenoside Rh2 could effectively reverse drug resistance in human colorectal carcinoma cell and its mechanism involved the prevention of cellular proliferation and migration, the promotion of cellular apoptosis and the alteration of drug-resistance genes, which suggested that Ginsenoside Rh2 may act as a promising candidate for drug resistance in human colorectal carcinoma chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.

    Article  PubMed  CAS  Google Scholar 

  2. Seow HF, Yip WK, Fifis T. Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther. 2016;9:1899–920.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol. 2014;20:9775–827.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. De Mattia E, Cecchin E, Toffoli G. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy. Drug Resist Updat. 2015;20:39–70.

    Article  PubMed  Google Scholar 

  5. Xiang Z, Kang QJ, Xiang X. Gene and protein expression in the oxaliplatin-resistant HT29/L-OHP human colon cancer cell line. Genet Mol Res. 2015;14:11013–22.

    Article  PubMed  CAS  Google Scholar 

  6. Wu S, Wen F, Li Y, et al. PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma. Tumour Biol. 2016;37:8799–809.

    Article  PubMed  CAS  Google Scholar 

  7. Khaleel SA, Al-Abd AM, Ali AA, et al. Didox and resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity. Sci Rep. 2016;6:36855.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Sui H, Zhou LH, Zhang YL, et al. Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF-kappaB Pathway in Colorectal Cancer. J Cell Biochem. 2016;117:1471–81.

    Article  PubMed  CAS  Google Scholar 

  9. Jin X, Che DB, Zhang ZH, et al. Ginseng consumption and risk of cancer: a meta-analysis. J Ginseng Res. 2016;40:269–77.

    Article  PubMed  Google Scholar 

  10. Xie J, Shao J, Lu Y, et al. Separation of ginseng active ingredients and their roles in cancer metastasis supplementary therapy. Curr Drug Metab. 2013;14:616–23.

    Article  PubMed  CAS  Google Scholar 

  11. Xu FY, Shang WQ, Yu JJ, et al. The antitumor activity study of ginsenosides and metabolites in lung cancer cell. Am J Transl Res. 2016;8:1708–18.

    PubMed  PubMed Central  CAS  Google Scholar 

  12. Dong H, Bai LP, Wong VK, et al. The in vitro structure-related anti-cancer activity of ginsenosides and their derivatives. Molecules. 2011;16:10619–30.

    Article  PubMed  Google Scholar 

  13. Wu N, Wu GC, Hu R, et al. Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128. Acta Pharmacol Sin. 2011;32:345–53.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Park HM, Kim SJ, Kim JS, et al. Reactive oxygen species mediated ginsenoside Rg3- and Rh2-induced apoptosis in hepatoma cells through mitochondrial signaling pathways. Food Chem Toxicol. 2012;50:2736–41.

    Article  PubMed  CAS  Google Scholar 

  15. Xia T, Wang JC, Xu W, et al. 20S-Ginsenoside Rh2 induces apoptosis in human Leukaemia Reh cells through mitochondrial signaling pathways. Biol Pharm Bull. 2014;37:248–54.

    Article  PubMed  CAS  Google Scholar 

  16. Han S, Jeong AJ, Yang H, et al. Ginsenoside 20(S)-Rh2 exerts anti-cancer activity through targeting IL-6-induced JAK2/STAT3 pathway in human colorectal cancer cells. J Ethnopharmacol. 2016;194:83–90.

    Article  PubMed  CAS  Google Scholar 

  17. Xie X, Eberding A, Madera C, et al. Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models. J Urol. 2006;175:1926–31.

    Article  PubMed  CAS  Google Scholar 

  18. Zhou B, Xiao X, Xu L, et al. A dynamic study on reversal of multidrug resistance by ginsenoside Rh(2) in adriamycin-resistant human breast cancer MCF-7 cells. Talanta. 2012;88:345–51.

    Article  PubMed  CAS  Google Scholar 

  19. Yang J, Yuan D, Xing T, et al. Ginsenoside Rh2 inhibiting HCT116 colon cancer cell proliferation through blocking PDZ-binding kinase/T-LAK cell-originated protein kinase. J Ginseng Res. 2016;40:400–8.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Chen Y, Liu ZH, Xia J, et al. 20(S)-ginsenoside Rh2 inhibits the proliferation and induces the apoptosis of KG-1a cells through the Wnt/beta-catenin signaling pathway. Oncol Rep. 2016;36:137–46.

    Article  PubMed  CAS  Google Scholar 

  21. Thwaites MJ, Cecchini MJ, Passos DT. Interchangeable roles for E2F transcriptional repression by the retinoblastoma protein and p27KIP1-cyclin-dependent kinase regulation in cell cycle control and tumor suppression. Mol Cell Biol. 2017;37:e00561–616.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Wang N, Wei H, Yin D, et al. MicroRNA-195 inhibits proliferation of cervical cancer cells by targeting cyclin D1a. Tumour Biol. 2016;37:4711–20.

    Article  PubMed  CAS  Google Scholar 

  23. Xiong L, Tang Y, Liu Z, et al. BCL-2 inhibition impairs mitochondrial function and targets oral tongue squamous cell carcinoma. Springerplus. 2016;5:1626.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Gao J, Yan Q, Liu S, et al. Knockdown of EpCAM enhances the chemosensitivity of breast cancer cells to 5-fluorouracil by downregulating the antiapoptotic factor Bcl-2. PLoS One. 2014;9:e102590.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Vegran F, Boidot R, Oudin C, et al. Overexpression of caspase-3 s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. Clin Cancer Res. 2006;12:5794–800.

    Article  PubMed  CAS  Google Scholar 

  26. Ueda M, Iguchi T, Nambara S, et al. Overexpression of transcription termination factor 1 is associated with a poor prognosis in patients with colorectal cancer. Ann Surg Oncol. 2015;22(Suppl 3):S1490–8.

    Article  PubMed  Google Scholar 

  27. Gao HX, Yan L, Li C, et al. miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1. Mol Med Rep. 2016;14:4135–43.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Schwab R, Micsik T, Szokoloczi O, et al. Functional evaluation of multidrug resistance transporter activity in surgical samples of solid tumors. Assay Drug Dev Technol. 2007;5:541–50.

    Article  PubMed  CAS  Google Scholar 

  29. Schmitt SM, Stefan K, Wiese M. Pyrrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1). Biochim Biophys Acta. 2017;1859:69–79.

    Article  PubMed  CAS  Google Scholar 

  30. Torres A, Vargas Y, Uribe D, et al. Adenosine A3 receptor elicits chemoresistance mediated by multiple resistance-associated protein-1 in human glioblastoma stem-like cells. Oncotarget. 2016;7:67373–86.

    PubMed  PubMed Central  Google Scholar 

  31. Gao M, Miao L, Liu M, et al. miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget. 2016;7:59714–26.

    PubMed  PubMed Central  Google Scholar 

  32. Samanian S, Mahjoubi F, Mahjoubi B, et al. MDR1 gene polymorphisms: possible association with its expression and clinicopathology characteristics in colorectal cancer patients. Asian Pac J Cancer Prev. 2011;12:3141–5.

    PubMed  Google Scholar 

  33. Januchowski R, Sterzynska K, Zaorska K, et al. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines. J Ovarian Res. 2016;9:65.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Chen YL, Yang TY, Wu CL, et al. Mechanisms underlying lung resistance-related protein (LRP)-mediated doxorubicin resistance of non-small cell lung cancer cells. Chin J Physiol. 2016;59:331–47.

    Article  PubMed  CAS  Google Scholar 

  35. Zhang W, Zhou H, Yu Y, et al. Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression. Onco Targets Ther. 2016;9:3359–68.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Bernig T, Ritz S, Brodt G, et al. Glutathione-S-transferases and chemotherapy resistance of Hodgkin’s lymphoma cell lines. Anticancer Res. 2016;36:3905–15.

    PubMed  CAS  Google Scholar 

  37. Liu S, Liu F, Jia H, et al. A glutathione S-transferase gene associated with antioxidant properties isolated from Apis cerana cerana. Naturwissenschaften. 2016;103:43.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anorectal Surgery, Cangzhou Central Hospital, No. 16 Xinhuaxi Road, Yunhe District, Cangzhou, 061000, Hebei Province, People’s Republic of China

    Gui-wei Liu, Yan-hua Liu, Guo-sheng Jiang & Wei-dan Ren

Authors
  1. Gui-wei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan-hua Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guo-sheng Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei-dan Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gui-wei Liu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Gw., Liu, Yh., Jiang, Gs. et al. The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. Human Cell 31, 189–198 (2018). https://doi.org/10.1007/s13577-017-0189-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-017-0189-3

Keywords

Search

Navigation